Hypertrophic cardiomyopathy (HCM) is the most common feline heart disease and is responsible for high morbidity and mortality rates. Sarcomere disorganization in the affected myocardium of cats with HCM is related to the myosin binding protein C (MYBPC3) gene mutation. In the diagnosis of human heart disease have increased the use of biomarkers such as natriuretic peptides ANP (atrial natriuretic peptide) and BNP (brain natriretic peptide) released by stress myocardial atria (ANP) and ventricular (BNP); cardiac troponin I (cTnI), sensitive and specific to diagnosis of myocardial infarction; and endothelin, a potent vasoconstrictor peptide whose plasma concentration increases in patients with heart failure (HF). HCM is diagnosed by conventional echocardiography (CE) through segmental or diffuse myocardial hypertrophy. Cardiac markers (ANP, BNP, cTnI and endothelin) will be determined after ECG, CE, digital thoracic radiography, measurement of blood pressure. Current research in veterinary medicine demonstrated significant differences in the measurement of ANP, BNP and endothelin compared to healthy animals, asymptomatic and symptomatic heart disease, and marked increase in the concentration of plasma cTnI in cats with HCM compared with healthy cats. The study will evaluate Maine Coon cats tested for genetically MYBPC3 mutation to demonstrate how changes in cardiac markers may help in early diagnosis of HCM which assists in medical treatment for the prevention of HF.
News published in Agência FAPESP Newsletter about the scholarship: